AR113931A1 - Tratamientos de combinación que comprenden la administración de 1h-pirazolo[4,3-b]piridinas - Google Patents
Tratamientos de combinación que comprenden la administración de 1h-pirazolo[4,3-b]piridinasInfo
- Publication number
- AR113931A1 AR113931A1 ARP180103639A ARP180103639A AR113931A1 AR 113931 A1 AR113931 A1 AR 113931A1 AR P180103639 A ARP180103639 A AR P180103639A AR P180103639 A ARP180103639 A AR P180103639A AR 113931 A1 AR113931 A1 AR 113931A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- fluoroalkyl
- optionally substituted
- cyano
- substituents selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: 1) Un primer compuesto de acuerdo con la fórmula (1) donde L se selecciona entre el grupo que consiste en NH, CH₂, S y O; R¹ se selecciona entre el grupo que consiste en hidrógeno, alquilo C₁₋₅ lineal o ramificado, fluoroalquilo C₁₋₅ y cicloalquilo C₃₋₅ monocíclico saturado; R² se selecciona entre el grupo que consiste en alquilo C₁₋₈ lineal o ramificado, cicloalquilo C₃₋₈ monocíclico saturado, oxetanilo, tetrahidrofuranilo y tetrahidropiranilo; todos los cuales pueden estar opcionalmente sustituidos una o más veces con uno o más sustituyentes seleccionados entre el grupo que consiste en metilo, flúor, hidroxi, ciano y metoxi; R³ es metilo sustituido con fenilo, piridonilo, piridinilo, pirimidinilo o pirazinilo, todos los cuales pueden estar opcionalmente sustituidos una o más veces con uno o más sustituyentes seleccionados entre el grupo que consiste en halógeno, ciano, alquilo C₁₋₃, fluoroalquilo C₁₋₃, fluoroalcoxi C₁₋₃ y alcoxi C₁₋₃; o R³ es metilo sustituido con un heteroarilo de 5 miembros que está opcionalmente sustituido con uno o más sustituyentes seleccionados entre halógeno, ciano, alquilo C₁₋₃, fluoroalquilo C₁₋₃, fluoroalcoxi C₁₋₃ y alcoxi C₁₋₃; o R³ es etilo sustituido con fenilo, piridonilo, piridinilo, pirimidinilo o pirazinilo todos los cuales pueden estar opcionalmente sustituidos una o más veces con uno o más sustituyentes seleccionados entre el grupo que consiste en halógeno, ciano, alquilo C₁₋₃, fluoroalquilo C₁₋₃, fluoroalcoxi C₁₋₃ y alcoxi C₁₋₃; o R³ es etilo sustituido con un heteroarilo de 5 miembros, que está opcionalmente sustituido con uno o más sustituyentes seleccionados entre halógeno, ciano, alquilo C₁₋₃, fluoroalquilo C₁₋₃, fluoroalcoxi C₁₋₃ y alcoxi C₁₋₃; o L es CH₂ y R³ es NH que está sustituido con fenilo, piridonilo, piridinilo, pirimidinilo o pirazinilo todos los cuales pueden estar opcionalmente sustituidos una o más veces con uno o más sustituyentes seleccionados entre el grupo que consiste en halógeno, ciano, alquilo C₁₋₃, fluoroalquilo C₁₋₃, fluoroalcoxi C₁₋₃ y alcoxi C₁₋₃; o L es CH₂ y R³ es NH que está sustituido con un heteroarilo de 5 miembros, que está opcionalmente sustituido con uno o más sustituyentes seleccionados entre halógeno, ciano, alquilo C₁₋₃, fluoroalquilo C₁₋₃, fluoroalcoxi C₁₋₃ y alcoxi C₁₋₃; R⁴ es fenilo, piridinilo o piridonilo todos los cuales pueden estar opcionalmente sustituidos una o más veces con uno o más sustituyentes seleccionados entre el grupo que consiste en halógeno, ciano, alquilo C₁₋₄, fluoroalquilo C₁₋₄, deutereoalquilo C₁₋₄, fluoroalcoxi C₁₋₃, ciclopropiloxi, alcoxi C₁₋₃, deutereoalcoxi C₁₋₃ y -N-R⁵R⁶, en el que R⁵ y R⁶ se seleccionan cada uno independientemente entre H, alquilo C₁₋₃ y deutereoalquilo C₁₋₃; o R⁴ es un heteroarilo de 5 miembros, que está opcionalmente sustituido con uno o más sustituyentes seleccionados entre halógeno, ciano, alquilo C₁₋₄, fluoroalquilo C₁₋₄, deutereoalquilo C₁₋₄, fluoroalcoxi C₁₋₃, ciclopropiloxi, alcoxi C₁₋₃, deutereoalcoxi C₁₋₃ y -N-R⁵R⁶, en el que R⁵ y R⁶ se seleccionan cada uno independientemente entre H, alquilo C₁₋₃ y deutereoalquilo C₁₋₃; o R⁴ es un heterociclo saturado de 4, 5 ó 6 miembros, todos los cuales pueden estar opcionalmente sustituidos con uno o más sustituyentes seleccionados entre oxo, alquilo C₁₋₄ y fluoroalquilo C₁₋₄; o una de sus sales farmacéuticamente aceptables, y 2) un segundo compuesto, compuesto que es útil en el tratamiento de un trastorno psiquiátrico, en donde 1) y 2) son para su uso combinado en el tratamiento de un trastorno psiquiátrico y/o cognitivo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201700708 | 2017-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR113931A1 true AR113931A1 (es) | 2020-07-01 |
Family
ID=64959282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180103639A AR113931A1 (es) | 2017-12-14 | 2018-12-13 | Tratamientos de combinación que comprenden la administración de 1h-pirazolo[4,3-b]piridinas |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11634416B2 (es) |
| EP (1) | EP3723807B1 (es) |
| JP (1) | JP7261801B2 (es) |
| KR (1) | KR20200099154A (es) |
| CN (1) | CN111465410B (es) |
| AR (1) | AR113931A1 (es) |
| AU (1) | AU2018385453B2 (es) |
| BR (1) | BR112019016815A2 (es) |
| CA (1) | CA3085201A1 (es) |
| CL (1) | CL2020001548A1 (es) |
| CO (1) | CO2020007129A2 (es) |
| CY (1) | CY1124751T1 (es) |
| ES (1) | ES2899868T3 (es) |
| HR (1) | HRP20211784T1 (es) |
| HU (1) | HUE057202T2 (es) |
| IL (1) | IL275290B2 (es) |
| LT (1) | LT3723807T (es) |
| MX (1) | MX2020006174A (es) |
| PL (1) | PL3723807T3 (es) |
| PT (1) | PT3723807T (es) |
| RS (1) | RS62551B1 (es) |
| RU (1) | RU2020118913A (es) |
| SG (1) | SG11202005361RA (es) |
| SI (1) | SI3723807T1 (es) |
| SM (1) | SMT202100655T1 (es) |
| WO (1) | WO2019115566A1 (es) |
| ZA (1) | ZA202003514B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| PL3723807T3 (pl) | 2017-12-14 | 2022-01-24 | H. Lundbeck A/S | Leczenie skojarzone obejmujące podawanie 1h-pirazolo[4,3-b]pirydyn |
| US11535611B2 (en) | 2017-12-20 | 2022-12-27 | H. Lundbeck A/S | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
| DE19942474A1 (de) | 1999-09-06 | 2001-03-15 | Merck Patent Gmbh | Pyrazolo[4,3-d]pyrimidine |
| MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| ATE415400T1 (de) | 2004-07-05 | 2008-12-15 | Astellas Pharma Inc | Pyrazolopyridinderivate |
| DE602005014375D1 (de) * | 2004-10-19 | 2009-06-18 | Neurocrine Biosciences Inc | Crf-rezeptor-antagonisten und zugehörige verfahren |
| US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| RU2402549C3 (ru) | 2005-04-14 | 2022-03-10 | Оцука Фармасьютикал Ко., Лтд. | Пиперазин-замещенные бензотиофены для лечения психических расстройств |
| WO2007071311A1 (en) | 2005-12-22 | 2007-06-28 | Newron Pharmaceuticals S.P.A. | 2 -phenylethylamino derivatives as calcium and/or sodium channel modulators |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| EP2089034A4 (en) | 2006-12-05 | 2010-07-28 | Intra Cellular Therapies Inc | NEW USES |
| CN103497185A (zh) * | 2007-03-14 | 2014-01-08 | 兰贝克赛实验室有限公司 | 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物 |
| US8697710B2 (en) | 2008-12-06 | 2014-04-15 | Intra-Cellular Therapies, Inc. | Optionally substituted 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo [3,4-d]pyrimidin-6(7H)-ones |
| CN102596221B (zh) | 2009-06-10 | 2019-06-04 | 纽约大学 | 病理tau蛋白的免疫靶向 |
| PL3042917T3 (pl) | 2010-08-12 | 2018-07-31 | Eli Lilly And Company | Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie |
| WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
| CA2831680C (en) | 2011-04-21 | 2020-04-21 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
| JP6100883B2 (ja) | 2012-03-19 | 2017-03-22 | アビデ セラピューティクス，インク． | カルバマート化合物、及びその製造並びに使用 |
| TW201533043A (zh) | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
| UA116023C2 (uk) | 2013-07-08 | 2018-01-25 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як антагоністи метаботропного глутаматного рецептора |
| KR20160115936A (ko) | 2014-02-19 | 2016-10-06 | 하. 룬드벡 아크티에셀스카브 | 알츠하이머병의 치료를 위한 bace1 저해제로서의 2-아미노-3,5,5-트리플루오로-3,4,5,6-테트라하이드로피리딘 |
| TWI599358B (zh) | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
| US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
| CA2961186A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic derivative |
| US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| JP2018508555A (ja) | 2015-03-16 | 2018-03-29 | 大日本住友製薬株式会社 | 二環性イミダゾロ誘導体 |
| US20160311831A1 (en) | 2015-04-22 | 2016-10-27 | H. Lundbeck A/S | Imidazotriazinones as PDE1 Inhibitors |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| US10206909B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| AU2016305275A1 (en) | 2015-08-12 | 2018-02-08 | H. Lundbeck A/S | 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors |
| WO2017100276A1 (en) | 2015-12-08 | 2017-06-15 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers |
| US10390177B2 (en) | 2015-12-09 | 2019-08-20 | Ford Global Technologies, Llc | Alert for left-behind mobile device |
| JP2019510039A (ja) | 2016-03-28 | 2019-04-11 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規組成物および方法 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JOP20190126A1 (ar) | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
| AR113926A1 (es) * | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| PL3723807T3 (pl) | 2017-12-14 | 2022-01-24 | H. Lundbeck A/S | Leczenie skojarzone obejmujące podawanie 1h-pirazolo[4,3-b]pirydyn |
| TW201927784A (zh) * | 2017-12-20 | 2019-07-16 | 丹麥商Ｈ 朗德貝克公司 | 作為pde1抑制劑之大環 |
| US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| US11535611B2 (en) * | 2017-12-20 | 2022-12-27 | H. Lundbeck A/S | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors |
-
2018
- 2018-12-12 PL PL18830163T patent/PL3723807T3/pl unknown
- 2018-12-12 LT LTEPPCT/EP2018/084432T patent/LT3723807T/lt unknown
- 2018-12-12 SG SG11202005361RA patent/SG11202005361RA/en unknown
- 2018-12-12 CN CN201880079962.7A patent/CN111465410B/zh active Active
- 2018-12-12 RS RS20211372A patent/RS62551B1/sr unknown
- 2018-12-12 RU RU2020118913A patent/RU2020118913A/ru unknown
- 2018-12-12 SM SM20210655T patent/SMT202100655T1/it unknown
- 2018-12-12 WO PCT/EP2018/084432 patent/WO2019115566A1/en active Application Filing
- 2018-12-12 MX MX2020006174A patent/MX2020006174A/es unknown
- 2018-12-12 SI SI201830453T patent/SI3723807T1/sl unknown
- 2018-12-12 HR HRP20211784TT patent/HRP20211784T1/hr unknown
- 2018-12-12 ES ES18830163T patent/ES2899868T3/es active Active
- 2018-12-12 HU HUE18830163A patent/HUE057202T2/hu unknown
- 2018-12-12 KR KR1020207019016A patent/KR20200099154A/ko not_active Ceased
- 2018-12-12 AU AU2018385453A patent/AU2018385453B2/en not_active Expired - Fee Related
- 2018-12-12 EP EP18830163.4A patent/EP3723807B1/en active Active
- 2018-12-12 JP JP2020531953A patent/JP7261801B2/ja active Active
- 2018-12-12 US US16/772,561 patent/US11634416B2/en active Active
- 2018-12-12 PT PT188301634T patent/PT3723807T/pt unknown
- 2018-12-12 BR BR112019016815A patent/BR112019016815A2/pt unknown
- 2018-12-12 CA CA3085201A patent/CA3085201A1/en active Pending
- 2018-12-13 AR ARP180103639A patent/AR113931A1/es unknown
-
2020
- 2020-06-10 CL CL2020001548A patent/CL2020001548A1/es unknown
- 2020-06-11 ZA ZA2020/03514A patent/ZA202003514B/en unknown
- 2020-06-11 IL IL275290A patent/IL275290B2/en unknown
- 2020-06-11 CO CONC2020/0007129A patent/CO2020007129A2/es unknown
-
2021
- 2021-11-25 CY CY20211101025T patent/CY1124751T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT3723807T (pt) | 2021-11-26 |
| SMT202100655T1 (it) | 2022-01-10 |
| RU2020118913A (ru) | 2022-01-14 |
| SI3723807T1 (sl) | 2022-01-31 |
| CN111465410B (zh) | 2022-10-25 |
| IL275290B2 (en) | 2023-06-01 |
| AU2018385453B2 (en) | 2024-02-08 |
| HUE057202T2 (hu) | 2022-04-28 |
| LT3723807T (lt) | 2021-12-10 |
| CY1124751T1 (el) | 2022-07-22 |
| SG11202005361RA (en) | 2020-07-29 |
| US11634416B2 (en) | 2023-04-25 |
| KR20200099154A (ko) | 2020-08-21 |
| CA3085201A1 (en) | 2019-06-20 |
| EP3723807B1 (en) | 2021-10-20 |
| BR112019016815A2 (pt) | 2020-04-07 |
| HRP20211784T1 (hr) | 2022-02-18 |
| MX2020006174A (es) | 2022-09-27 |
| EP3723807A1 (en) | 2020-10-21 |
| JP7261801B2 (ja) | 2023-04-20 |
| IL275290A (en) | 2020-07-30 |
| US20200385381A1 (en) | 2020-12-10 |
| ZA202003514B (en) | 2022-12-21 |
| CO2020007129A2 (es) | 2020-06-19 |
| PL3723807T3 (pl) | 2022-01-24 |
| CL2020001548A1 (es) | 2020-09-25 |
| RS62551B1 (sr) | 2021-12-31 |
| JP2021506775A (ja) | 2021-02-22 |
| CN111465410A (zh) | 2020-07-28 |
| ES2899868T3 (es) | 2022-03-15 |
| AU2018385453A1 (en) | 2020-07-02 |
| WO2019115566A1 (en) | 2019-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR113931A1 (es) | Tratamientos de combinación que comprenden la administración de 1h-pirazolo[4,3-b]piridinas | |
| AR110405A1 (es) | Compuestos | |
| AR094342A1 (es) | Derivados de ácido borónico útiles como agentes antimicrobianos | |
| AR094911A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃ | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR112348A1 (es) | Compuestos bicíclicos de pirazolo y triazolo como inhibidores de quinasas jak | |
| AR086817A1 (es) | Compuestos inhibidores de la fosfodiesterasa tipo 10a | |
| AR112290A1 (es) | Dinucleótidos cíclicos como agentes anticáncer | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR109709A1 (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| AR106053A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer | |
| AR094857A1 (es) | Derivados de pirrolo[2,3-d]pirimidina | |
| AR091271A1 (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa | |
| AR113926A1 (es) | Derivados de 1h-pirazolo[4,3-b]piridinas | |
| AR089623A1 (es) | Inhibidores de iap | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR103566A1 (es) | Compuestos derivados de heteroarilo y heterociclo condensados | |
| AR109776A1 (es) | Compuestos de p2x₃ y/o p2x₂/₃ y métodos | |
| AR094797A1 (es) | Derivados de pirrolotriazina como inhibidores de pi3k | |
| AR114465A1 (es) | Compuestos de pirazol sustituidos con heteroarilo y su utilización farmacéutica | |
| AR095267A1 (es) | Compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| AR101222A1 (es) | Derivados de piridona | |
| AR111252A1 (es) | Compuestos de isoxazol carboxamida y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |